Last updated: April 24, 2026
What does Brazil patent BR112016023422 cover, and how does it fit the Brazil drug-patent landscape?
BR112016023422 is a Brazilian patent application/publication filed in 2016 under the number BR 112016023422. A complete, claim-level and scope-level analysis requires access to the published claims/specification text for this specific document (and, where applicable, the granted status). This content is not present in the information provided here, so a complete and accurate scope/claims and an evidence-based landscape mapping cannot be produced.
Scope and claims: what is protected under BR112016023422?
A scope and claims analysis must rest on the exact language of:
- the independent claims (composition, formulation, method, use, process, or device),
- the dependent claims (specific embodiments, ranges, salts/polymorphs, excipients, dosing, regimens, manufacturing steps),
- the definitions and claim dependencies,
- the examples and any support for enablement that constrain interpretation.
Without the claims text and the specification for BR112016023422, any attempt to summarize would risk factual error and incorrect claim construction.
Claim structure: how broad or narrow is the protection likely to be?
A credible breadth assessment requires:
- whether protection is compound-of-interest versus formulation versus method/use,
- claim construction signals such as open vs closed language (“comprising” vs “consisting of”), functional limitations, Markush scope, and range boundaries,
- presence/absence of product-by-process language,
- whether key claim elements are limited by specific exemplified parameters.
Those signals are claim-text dependent and not available here.
Patent landscape in Brazil: what competitors and related filings likely surround BR112016023422?
A landscape study must map, at minimum, the following in Brazil (INPI) and related jurisdictions for the same therapeutic asset(s):
- same priority family continuation paths,
- Brazilian filings by likely competitors (same molecules, salts, polymorphs, formulations, dosing regimens),
- closest INPI prosecution siblings (amendment/objection patterns can indicate scope),
- whether there are Bolar-type exceptions, regulatory-driven enforcement gaps, and whether the asset is covered by local patent term adjustments or extensions where relevant.
This requires the patent family identity for BR112016023422 (same active ingredient, salt/form, and use), which is not supplied here. Without it, landscape mapping would be speculative.
Freedom-to-operate indicators: what matters for Brazil enforcement risk?
Brazil FTO risk indicators are driven by:
- whether the claims are directed to composition (stronger for generic entry barriers),
- whether claims are method-of-treatment (often assessed differently in enforcement),
- whether there are combination claims that block substitution,
- whether claim scope is constrained by the specification support,
- the status in Brazil (pending vs granted vs lapsed) and any judicial or administrative events.
None of these can be tied to BR112016023422 without its claim set and status.
Practical outcomes for R&D and investment
A complete deliverable would normally include:
- A claim-by-claim table (independent and dependent claims).
- A “coverage map” by claim element (API, salt/polymorph, excipients, ratios, particle size, manufacturing steps, dosage regimen).
- A family chart: priorities, filings, granted jurisdictions, and claim amendments.
- A Brazil-specific landscape: nearest INPI publications/grants for same asset class and formulation class.
- A risk matrix for generic/combination entrants and likely design-around routes grounded in claim language.
This is not possible without the underlying document content.
Key Takeaways
- BR112016023422 cannot be analyzed for scope or claims here because the specific published claim/specification text and status are not provided.
- A Brazil patent landscape assessment requires the patent family identity tied to BR112016023422. That identity is not available in the provided material.
- To produce an accurate, investment-grade analysis, the document text and bibliographic status must be used as primary evidence.
FAQs
-
Is BR112016023422 a granted Brazilian patent or a pending application?
Not determinable from the information provided.
-
Does BR112016023422 likely cover a drug substance, a formulation, or a method of use?
Not determinable without the claims/specification for the publication.
-
How is claim breadth assessed in Brazil drug patents?
By independent claim construction and dependent claim scope, range language, structural vs functional limits, and enablement support. The claim text for BR112016023422 is required.
-
How do you map the competitive landscape for a Brazil drug patent?
By linking the patent family (active ingredient/salt/form/use) and then searching Brazil INPI publications and grants for overlapping claim elements. The family linkage is not provided.
-
What drives freedom-to-operate risk for Brazil pharmaceuticals?
Claim direction (composition vs method), claim breadth, status (granted vs pending), and enforceability. BR112016023422 status and claim language are not provided.
References
[1] INPI. Brazil patent documents database (publication/patent bibliographic records).
